New IV antibiotic now available to UK patients

New IV antibiotic now available to UK patients

A new intravenous antibiotic that could benefit patients and help reduce pressure on hospitals is now available in the UK.

Xydalba (dalbavancin hydrochloride) is an IV antibiotic approved by the European Medicines Agency for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.

It is the first and only option for ABSSSI that offers a complete course of IV therapy delivered as a single 30-minute infusion.

Compared to other IV antibiotics that may need to be administered for up to 14 days and can require hospitalisation, in clinical trials Xydalba successfully treated a majority of patients as outpatients.

Xydalba’s clinical development programme also demonstrated that it was as effective and as well tolerated as other intravenous antibiotics. It was also shown to be as effective against MSSA and MRSA bacteria.

ABSSSI can be potentially life-threatening. They include conditions such as cellulitis/erysipelas, wound infections and major skin abscesses.

There are more than 290,000 estimated cases of serious skin infections in the UK, with 79% receiving IV antibiotics as a first line treatment. Cellulitis accounts for 8% of emergency hospital admissions.

At present, IV antibiotic treatment for ABSSSI can be administered in the hospital, through outpatient departments, or OPAT (Outpatient Parenteral Antimicrobial Therapy) centres.

There are many health and social issues, such as a challenging home environment, inadequate transport or a lack of available support from family or caregivers which can exclude patients from OPAT services.

This results in admission and a period of time in hospital.  Xydalba can be delivered in one or two-doses and offers the opportunity for these patients to be treated and discharged home.

Over 15,000 patients have already been treated with dalbavancin globally and no unexpected trends or new safety signals were identified.

Xydalba is classified as a ‘narrow spectrum’ antibiotic. Government guidelines currently recommend the use of narrow spectrum antibiotics, where appropriate, to help prevent antibiotic resistance.